CalciMedica Announced Late-breaking Positive Data From The Phase 2B Carpo Trial Of Auxora In Acute Pancreatitis (ap) With Accompanying Systemic Inflammatory Response Syndrome (sirs) At The American College Of Gastroenterology 2024
Portfolio Pulse from Benzinga Newsdesk
CalciMedica announced positive results from its Phase 2B Carpo trial of Auxora for treating acute pancreatitis with systemic inflammatory response syndrome. The data was presented at the American College of Gastroenterology 2024.
October 30, 2024 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CalciMedica's positive Phase 2B trial results for Auxora in treating acute pancreatitis with SIRS could boost investor confidence and potentially impact stock prices positively.
The announcement of positive trial results is a significant milestone for CalciMedica, likely to enhance investor sentiment and drive stock prices up. The presentation at a major conference further validates the findings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100